Additionally, treatment with the PPARα agonist, fenofibrate, effectively repressed Fabp3-KO induced cardiac hypertrophy, highlighting a potential clinical value of hypertrophic treatment by targeting cardiac energy metabolism. Here, FABP3 is linked to cardiac hypertrophy.